Latest Press Releases

Europes Main Computational Biology Conference Comes to Turku, Finland

Discoveries made when biology meets computational sciences are revolutionising the landscape of life sciences and healthcare. Computational biology and bioinformatics are driving this transformation helping researchers analyse vast amounts of ...

Derm-biome Pharmaceuticals' Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers With No Observable Side Effects

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 ...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and ...

Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting

- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif. , Nov. 15, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. ...

Press Releases

Premium Press Releases »

Europes Main Computational Biology Conference Comes to Turku, Finland

Derm-biome Pharmaceuticals' Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers With No Observable Side Effects

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

Press Releases »

Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting

Medindia Newsletters